41 results on '"Hogan, William J."'
Search Results
2. EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant
3. Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
4. Pulmonary function and long-term survival in patients with PERDS after autologous hematopoietic stem cell transplantation
5. Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study
6. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
7. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
8. Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
9. Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
10. High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant
11. Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
12. Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis
13. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
14. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
15. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
16. Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation
17. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant
18. Risk of relapse in patients receiving azithromycin after allogeneic HSCT
19. Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths
20. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant
21. The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma
22. Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function
23. Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant
24. Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
25. Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH‐based algorithm distinguishes prognostic groups and outcomes
26. Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
27. Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a ‘graft versus host’-like syndrome and poor outcomes
28. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
29. Mayo Clinic experience with 1123 adults with acute myeloid leukemia
30. Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure
31. Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma
32. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation
33. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis
34. Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
35. Use of autologous stem cells cryopreserved for over 15 years in stem cell transplantation for multiple myeloma
36. Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis
37. Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis
38. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
39. Momelotinib therapy for myelofibrosis: a 7-year follow-up
40. Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
41. Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.